Effect of Esketamine on Postoperative Depression、Gut Microbiota、Bispectral Index Data of Depression Patients Undergoing Breast Cancer Operation (ESPOD-BI)

Summary

This study is a prospective, randomized, controlled (randomized, parallel group, concealed allocation), double-blinded trial. All depression patients undergoing breast cancer operation will be randomized 1:1 to the treatment intervention with general anesthesia as an adjunct to esketamine or saline. The objective of the trial is to evaluate the postoperative depression、gut microbiota、bispectral index data of patients undergoing breast cancer operation with esketamine or saline.

Eligibility

Inclusion Criteria:

* At least18 years and pre-menopausal;
* scheduled to undergo elective breast cancer operation;
* American Society of Anaesthesiologists (ASA) risk classification I-II.
* Montgomery-asberg Depression Rating Scale (MADRS) score ≥22

Exclusion Criteria:

* Cognitive difficulties
* Partial or complete gastrectomy
* Previous esophageal surgery
* Inability to conform to the study's requirements
* Ongoing participation or participation in another study \<1 month ago

Conditions3

Interventions2

Related trials

• Determination of ED50 and ED95 With Clinical Efficacy of Intranasal Dexmedetomidine Combined With Esketamine for Preoperative Sedation in Pediatric General Anesthesia — Second Affiliated Hospital of Wenzhou Medical University
• Effect of Low-dose EsketaMine on dElirium in High-risk Elderly Patients uNdergoing elecTive Surgery (ELEMENT) — Nanfang Hospital, Southern Medical University
• Effects of Epidural Labor Analgesia With Esketamine on the Incidence of Postpartum Depression in Parturients — Women's Hospital School Of Medicine Zhejiang University
• Esketamine Combined With Remimazolam on Postoperative Sleep Disturbance and Anxiety in Patients — Tianjin Medical University General Hospital
• Esketamine in Microelectrode Recording-guided Subthalamic Deep-Brain Stimulation for Parkinson's Disease — Beijing Tiantan Hospital
• Metabolic Profiling of Esketamine Treatment in Depressive Disorder — University of Zagreb
• Personalized DBS Targeting for Treating Depression — Second Affiliated Hospital, School of Medicine, Zhejiang University
• A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder — Janssen Research & Development, LLC

Browse More Trials